https://www.taxtmi.com/news?id=64346 Board-approved INR 110 crore capex will expand Dahej capacities for commercial-scale plant-based Vitamin D3 with process patent protection, enlarge production of CAL-B lipase and Penicillin G Acylase to support sustainable biocatalysis for semi-synthetic antibiotics, and establish commercial manufacture of high-value Vitamin D3 derivatives such as calcifediol, with implementation phased over two financial years using internal accruals and debt. en-us Thu, 11 Dec 2025 10:46:03 +0530 Thu, 11 Dec 2025 10:46:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=64346 Board-approved INR 110 crore capex will expand Dahej capacities for commercial-scale plant-based Vitamin D3 with process patent protection, enlarge production of CAL-B lipase and Penicillin G Acylase to support sustainable biocatalysis for semi-synthetic antibiotics, and establish commercial manufacture of high-value Vitamin D3 derivatives such as calcifediol, with implementation phased over two financial years using internal accruals and debt. News - Thu, 11 Dec 2025 10:46:03 +0530 https://www.taxtmi.com/news?id=64346